Arrowhead Eager To Take On ‘Straightforward’ NASH Approach Abandoned By J&J

 
• By Joseph Haas

J&J pipeline review results in return of PNPLA3-targeted NASH candidate optioned under 2018 alliance, but the fate of a hepatitis B candidate included in that deal is undetermined so far.

Arrowheads
Arrowhead will take over NASH candidate once licensed to J&J • Source: Shutterstock

More from Strategy

More from Business